Cargando…

Oral Treatments With the TrkB Ligand Prodrug, R13, Promote Enhanced Axon Regeneration Following Peripheral Nerve Injury

Axon regeneration after peripheral nerve injury is slow and inefficient, leading to generally poor functional recovery. Activity-dependent experimental therapies that increase expression of brain-derived neurotrophic factor (BDNF) and its TrkB receptors enhance regeneration, suggesting that treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: English, Arthur W., Carrasco, Dario, Hoffman, Dustin, Isaacson, Robin, Kang, Seong Su, Khan, Samia, Liu, Xia, Ye, Keqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051483/
https://www.ncbi.nlm.nih.gov/pubmed/35496909
http://dx.doi.org/10.3389/fncel.2022.857664
_version_ 1784696567466295296
author English, Arthur W.
Carrasco, Dario
Hoffman, Dustin
Isaacson, Robin
Kang, Seong Su
Khan, Samia
Liu, Xia
Ye, Keqiang
author_facet English, Arthur W.
Carrasco, Dario
Hoffman, Dustin
Isaacson, Robin
Kang, Seong Su
Khan, Samia
Liu, Xia
Ye, Keqiang
author_sort English, Arthur W.
collection PubMed
description Axon regeneration after peripheral nerve injury is slow and inefficient, leading to generally poor functional recovery. Activity-dependent experimental therapies that increase expression of brain-derived neurotrophic factor (BDNF) and its TrkB receptors enhance regeneration, suggesting that treatments with BDNF might also be effective. However, recombinant human BDNF (rhBDNF), as well as 7,8-dihydroxyflavone (7,8-DHF), a small molecular BDNF mimetic, may have limited treatment applications because of their modest oral bioavailability and pharmacokinetic profile. R13 is a 7,8-DHF prodrug. Upon oral administration, it is converted in the liver to 7,8-DHF. In immunoblots from tissues at the site of nerve injury, a single oral treatment with R13 to mice following sciatic nerve transection and repair produced a rapid and prolonged increase in immunoreactivity to phosphorylated TrkB, prolonged phosphorylation of mitogen activated protein kinase (MAPK/Erk1/2), and a rapid but transient increase in phosphorylated AKT (protein kinase B). Intramuscular injections of fluorescent retrograde tracers into the gastrocnemius and tibialis anterior muscles 4 weeks after nerve injury resulted in significantly greater numbers of labeled motoneurons and dorsal root ganglion neurons in R13-treated mice than in vehicle-treated controls. Direct electromyographic (EMG) responses (M waves) were significantly larger in R13-treated mice 4 weeks after injury than vehicle-treated controls or mice treated with oral 7,8-DHF. Oral treatments with the prodrug, R13, are a potent therapy for stimulating axon regeneration and functional recovery after peripheral nerve injury.
format Online
Article
Text
id pubmed-9051483
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90514832022-04-30 Oral Treatments With the TrkB Ligand Prodrug, R13, Promote Enhanced Axon Regeneration Following Peripheral Nerve Injury English, Arthur W. Carrasco, Dario Hoffman, Dustin Isaacson, Robin Kang, Seong Su Khan, Samia Liu, Xia Ye, Keqiang Front Cell Neurosci Cellular Neuroscience Axon regeneration after peripheral nerve injury is slow and inefficient, leading to generally poor functional recovery. Activity-dependent experimental therapies that increase expression of brain-derived neurotrophic factor (BDNF) and its TrkB receptors enhance regeneration, suggesting that treatments with BDNF might also be effective. However, recombinant human BDNF (rhBDNF), as well as 7,8-dihydroxyflavone (7,8-DHF), a small molecular BDNF mimetic, may have limited treatment applications because of their modest oral bioavailability and pharmacokinetic profile. R13 is a 7,8-DHF prodrug. Upon oral administration, it is converted in the liver to 7,8-DHF. In immunoblots from tissues at the site of nerve injury, a single oral treatment with R13 to mice following sciatic nerve transection and repair produced a rapid and prolonged increase in immunoreactivity to phosphorylated TrkB, prolonged phosphorylation of mitogen activated protein kinase (MAPK/Erk1/2), and a rapid but transient increase in phosphorylated AKT (protein kinase B). Intramuscular injections of fluorescent retrograde tracers into the gastrocnemius and tibialis anterior muscles 4 weeks after nerve injury resulted in significantly greater numbers of labeled motoneurons and dorsal root ganglion neurons in R13-treated mice than in vehicle-treated controls. Direct electromyographic (EMG) responses (M waves) were significantly larger in R13-treated mice 4 weeks after injury than vehicle-treated controls or mice treated with oral 7,8-DHF. Oral treatments with the prodrug, R13, are a potent therapy for stimulating axon regeneration and functional recovery after peripheral nerve injury. Frontiers Media S.A. 2022-04-15 /pmc/articles/PMC9051483/ /pubmed/35496909 http://dx.doi.org/10.3389/fncel.2022.857664 Text en Copyright © 2022 English, Carrasco, Hoffman, Isaacson, Kang, Khan, Liu and Ye. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular Neuroscience
English, Arthur W.
Carrasco, Dario
Hoffman, Dustin
Isaacson, Robin
Kang, Seong Su
Khan, Samia
Liu, Xia
Ye, Keqiang
Oral Treatments With the TrkB Ligand Prodrug, R13, Promote Enhanced Axon Regeneration Following Peripheral Nerve Injury
title Oral Treatments With the TrkB Ligand Prodrug, R13, Promote Enhanced Axon Regeneration Following Peripheral Nerve Injury
title_full Oral Treatments With the TrkB Ligand Prodrug, R13, Promote Enhanced Axon Regeneration Following Peripheral Nerve Injury
title_fullStr Oral Treatments With the TrkB Ligand Prodrug, R13, Promote Enhanced Axon Regeneration Following Peripheral Nerve Injury
title_full_unstemmed Oral Treatments With the TrkB Ligand Prodrug, R13, Promote Enhanced Axon Regeneration Following Peripheral Nerve Injury
title_short Oral Treatments With the TrkB Ligand Prodrug, R13, Promote Enhanced Axon Regeneration Following Peripheral Nerve Injury
title_sort oral treatments with the trkb ligand prodrug, r13, promote enhanced axon regeneration following peripheral nerve injury
topic Cellular Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051483/
https://www.ncbi.nlm.nih.gov/pubmed/35496909
http://dx.doi.org/10.3389/fncel.2022.857664
work_keys_str_mv AT englisharthurw oraltreatmentswiththetrkbligandprodrugr13promoteenhancedaxonregenerationfollowingperipheralnerveinjury
AT carrascodario oraltreatmentswiththetrkbligandprodrugr13promoteenhancedaxonregenerationfollowingperipheralnerveinjury
AT hoffmandustin oraltreatmentswiththetrkbligandprodrugr13promoteenhancedaxonregenerationfollowingperipheralnerveinjury
AT isaacsonrobin oraltreatmentswiththetrkbligandprodrugr13promoteenhancedaxonregenerationfollowingperipheralnerveinjury
AT kangseongsu oraltreatmentswiththetrkbligandprodrugr13promoteenhancedaxonregenerationfollowingperipheralnerveinjury
AT khansamia oraltreatmentswiththetrkbligandprodrugr13promoteenhancedaxonregenerationfollowingperipheralnerveinjury
AT liuxia oraltreatmentswiththetrkbligandprodrugr13promoteenhancedaxonregenerationfollowingperipheralnerveinjury
AT yekeqiang oraltreatmentswiththetrkbligandprodrugr13promoteenhancedaxonregenerationfollowingperipheralnerveinjury